InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,123.21
(
1.17%
)
US TECH 100
17,401.96
(
1.91%
)
Dow Jones
38,649.61
(
1.11%
)
Brent Oil
83.19
(
-0.53%
)
Bitcoin
61,606.20
(
4.20%
)
Post# of 251697
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DewDiligence post# 170370

Friday, 11/22/2013 9:00:54 PM

Friday, November 22, 2013 9:00:54 PM

Post# of 251697
Just went through NVS investor day presentation today. As rumored on twitter the past two weeks, it will bring ABL001, a new BCR-ABL inhibitor to clinic in 1H2014. ABL001/Nilotinib combination appears to prevent emergence of resistance including T315I mutation as appeared on page 177 of presentation.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up